Skip to contentpdufa.bio
Home › Decisions › AZN 2026-11-16

AZN FDA decision: Nov 13, 2026 (announced Nov 16)

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET
✓ APPROVED

Klygefa (gefurulimab-gaks) was approved by the FDA on November 13, 2026 to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, the 50th novel drug approval of 2026 on the FDA's Novel Drug Approvals list.

Verified against: FDA action day November 13, 2026 (BLA 761488 ORIG-1 (FDA letter)) · Announcement November 16, 2026 · Goal date: none on record.

This page was first committed to pdufa.bio's public repository on Nov 21, 2026, 9:14 AM ET (public commit 012d17f). Dates on this page are the FDA's and the sponsor's; this line is ours.

Run-up into the decision (T-120 → T+3)

announced 11/16/26$195.15$155.625/27/26announced 11/16/26$195.15$155.625/27/26
Daily close, T-120 (5/27/26) through T+3. Run-up high $195.15 on 7/2/26, low $155.62 on 8/4/26 (T-120 to T-1). Announced 11/16/26 (FDA action 11/13/26). Historical price action, not a forecast.

Key facts

FDA decision date2026-11-13
Announced2026-11-16
OutcomeApproved
Drug / candidateKlygefa (gefurulimab-gaks)
IndicationGeneralized myasthenia gravis in adults who are anti-AChR antibody positive
CompanyAstraZeneca PLC (Alexion)
Market-cap tierLarge
120-day run-up (T-120→T-1)-1.5%
Decision-day move-0.2%
Move measured on2026-11-16 close (the announcement day), against the 2026-11-13 close
Cohort decision-day move (history)1.0% median (n=647)

The FDA's approval letter for BLA 761488, signed November 13, 2026 (FDA letter), covers Klygefa (gefurulimab-gaks) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody positive. The letter states that the application was received on November 13, 2025, and it approves a REMS because of the risk of serious meningococcal infections. AstraZeneca announced the approval on November 16, 2026 and describes once-weekly subcutaneous self-administration by autoinjector (AstraZeneca, November 16, 2026). Per AstraZeneca, in the Phase III PREVAIL trial (260 patients) the MG-ADL total score improved more than with placebo at week 26 (treatment difference -1.6, p<0.0001). We hold no publicly disclosed PDUFA goal date for this application, so no early or late margin is given.

Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.

Primary source: FDA approval letter, BLA 761488, November 13, 2026

FDA record of the action: the FDA approved on November 13, 2026, per BLA 761488 ORIG-1 (FDA letter). The sponsor announced it on November 16, 2026. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.

Specialist biotech funds holding AZN, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors379,300$61.8 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

Was Klygefa (gefurulimab-gaks) approved by the FDA?

Yes. The FDA approved the application for Klygefa (gefurulimab-gaks) on November 13, 2026, per the FDA's own record. The company announced it on November 16, 2026. The primary source is linked on this page.

Which company is behind Klygefa (gefurulimab-gaks)?

Klygefa (gefurulimab-gaks) is an AstraZeneca PLC (Alexion) (AZN) program. The FDA decision came on November 13, 2026; the FDA's own record of the decision is linked on this page.

How did AZN stock react to the FDA decision?

AZN moved -0.2%, measured as the 2026-11-16 close (the announcement day) against the 2026-11-13 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.

Is gefurulimab approved by the FDA?

Yes. The FDA approved Klygefa (gefurulimab-gaks) on November 13, 2026 for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive (BLA 761488). AstraZeneca announced it on November 16, 2026.

How is Klygefa given?

Per AstraZeneca, Klygefa is self-administered under the skin once a week with an autoinjector. The FDA letter approves a REMS because of the risk of serious meningococcal infections.

Was the Klygefa decision early or late?

pdufa.bio holds no publicly disclosed PDUFA goal date for this application, so no margin is given. The FDA letter states that the application was received on November 13, 2025.